Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Double-blind, Placebo-controlled, 18-mon Ext Study Long-term Efficacy & Safety of 50 & 100mg/Day Doses of Safinamide, as add-on Therapy, in Idiopathic PD Pts With Motor Fluctuations, Treated With Levodopa, Who May be Receiving DA, and/or Anticholinergic

Trial Profile

A Phase III, Double-blind, Placebo-controlled, 18-mon Ext Study Long-term Efficacy & Safety of 50 & 100mg/Day Doses of Safinamide, as add-on Therapy, in Idiopathic PD Pts With Motor Fluctuations, Treated With Levodopa, Who May be Receiving DA, and/or Anticholinergic

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Safinamide (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Newron Pharmaceuticals; Newron Sweden AB
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Mar 2018 Results of a new post hoc analysis of the data from this study assessing the long-term (2-year) efficacy of safinamide on parkinsons disease chronic pain, published in the Advances in Therapy Journal.
    • 27 Jun 2017 Results of post-hoc analysis assessing long term efficacy, presented at the 3rd Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top